key: cord-1025353-yl1p67sf
authors: Nawa, Nobutoshi; Kuramochi, Jin; Sonoda, Shiro; Yamaoka, Yui; Nukui, Yoko; Miyazaki, Yasunari; Fujiwara, Takeo
title: Seroprevalence of SARS‐CoV‐2 in Utsunomiya City, Greater Tokyo, after the first pandemic in 2020
date: 2020-12-16
journal: J Gen Fam Med
DOI: 10.1002/jgf2.408
sha: bbabbcdd251e5824860d8647ea3363fed75312fd
doc_id: 1025353
cord_uid: yl1p67sf

BACKGROUND: A seroepidemiological study was conducted on a random sample of households in Utsunomiya City, Tochigi Prefecture, Greater Tokyo, Japan, to assess the seroprevalence of SARS‐CoV‐2. METHODS: The level of IgG antibodies in the blood of the recruited subjects was assessed using chemiluminescence immunoassay analysis. In addition, the population‐based prevalence of SARS‐CoV‐2 was estimated. RESULTS: Three positive afebrile cases were confirmed. The estimated unweighted prevalence and weighted prevalence of SARS‐CoV‐2 infection were 0.40% and 1.23%, respectively. CONCLUSIONS: This study suggests that the prevalence of SARS‐CoV‐2 may have been underestimated. Wider testing strategies may lead to revealing more SARS‐CoV‐2 cases.

conducted between June 14, 2020, and July 5, 2020, that is, between the first and second waves of the pandemic. 5 Invitations enclosed with a questionnaire were sent to 2290 people in 1000 households randomly selected from Utsunomiya City's basic resident registry. Written informed consent was obtained from all the participants. The level of IgG antibodies in the blood of the participants was assessed using chemiluminescence immunoassay analysis (Shenzhen YHLO Biotech Co., Ltd., Shenzhen, China). 6 According to the manufacturer, the sensitivity and specificity of the assay with a cutoff value of 10 AU/ml were 97.3% and 96.3%, respectively.

Confidence intervals for unweighted seroprevalence were calculated using the exact binomial distribution. Furthermore, multiple imputation was applied to estimate the population-based weighted prevalence using baseline data from the registry, including age, gender, distance to clinic, residential district, and the number of cohabitants of participants and nonparticipants, considering the difference between participants and nonparticipants. Confidence intervals for weighted seroprevalence were calculated 50 times using the logit-transformed standard error and then combined using Rubin's rules. The analysis was performed in Stata 14 (StataCorp LP, College Station, TX, USA) and R version 3.6.0 (R Core Team, 2019). The study was approved by the research ethics committee at Tokyo Medical and Dental University. and weighted prevalence of SARS-CoV-2 infection were 0.40% (95% confidence interval: 0.08%-1.18%) and 1.23% (95% confidence interval: 0.17%-2.28%), respectively (Table 1 ).

The unweighted seroprevalence and weighted seroprevalence of SARS-CoV-2 in Utsunomiya City of Japan were found to be 0.40% and 1.23%, respectively, much lower than that in Los Angeles, United States (4.31%). 7 These results suggest that the majority of the population in Utsunomiya City was not infected. However, the number of unweighted and weighted estimated cases was 2,074 and The main limitation of the study is the low participation rate. Further prospective studies with the same cohort would enable monitoring SARS-CoV-2 antibody levels.

We thank Yuna Koyama, Hisaaki Nishimura, Euma Ishii, Yoshifumi Fukuya, Keitaro Miyamura, and Yu Funakoshi. We also thank medical students at TMDU who participated in the data collection, medical staff in Kuramochi Clinic Interpark, and all the participants in this study.

Authors declare no conflict of interests for this article.

Nobutoshi Nawa https://orcid.org/0000-0001-6785-7867

Situation report -168

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

WHO Scientific and Technical Advisory Group for Infectious Hazards. COVID-19: what is next for public health?

Updates on COVID-19 in Japan

COVID-19 cases in Utsunomiya city

Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019

Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults